Introduction
============

Glaucoma is defined as progressive optic neuropathy that results in irreversible visual field loss \[[@r1],[@r2]\]. Glaucoma is the second leading cause of blindness in the world \[[@r3]\]. Primary open angle glaucoma (POAG) is the most common type of glaucoma, affecting almost 2% of the world's population \[[@r4]\]. India has a high prevalence of glaucoma with POAG being the most common type \[[@r5]\]. The prevalence of POAG in south Indian populations is about 1.6% \[[@r6],[@r7]\] which is similar to that observed in Western populations.

Among the various risk factors, a positive family history of POAG is considered a major risk factor. Approximately, 16%--22% of first degree relatives of POAG patients develop the disease \[[@r8],[@r9]\]. POAG is a complex heterogeneous disease from the number of loci, genes, and mutations involved. A recent review \[[@r10]\] lists 14 chromosomal loci for POAG as per [HUGO](http://www.genenames.org/index.html) (Human Genome Organization) \[[@r11]-[@r18]\]. Mutations in three genes namely, myocilin (*MYOC*, earlier called as the *TIGR*- Trabecular meshwork Inducible Glucocorticoid Response gene), optineurin (*OPTN*), and W (tryptophan) D (aspartic acid) repeat 36 (*WDR36*) have been identified among POAG patients \[[@r19]-[@r24]\]. Polymorphisms in cytochrome P450 1B1 (*CYP1B1*) \[[@r25],[@r26]\] and heat shock protein 70-1 (*HSP 70-1*) \[[@r27]\] have been reported among POAG patients. Recently, the tumor protein 53 (*p53*) codon 72 polymorphism (variant [rs1042522](http://www.ncbi.nlm.nih.gov/snp?term=rs1042522)) was suggested to be an increased risk factor for POAG in Caucasians \[[@r28]\], while another study from Turkey did not find such an association \[[@r29]\]. Opticin (*OPTC*) as a possible candidate gene for POAG has been suggested \[[@r30]\].

Stone et al. \[[@r19]\] were the first to report mutations in *MYOC* among POAG patients. Since then, many sequence alterations have been reported in *MYOC* among POAG patients, worldwide \[[@r31]-[@r45]\]. Mutations in *MYOC* have been observed in the juvenile and adult onset forms of POAG. Mutations have also been reported among both familial and sporadic cases of POAG \[[@r19]\]. A few variants are recurrent in various populations world-wide while some mutations were observed to be ethnicity specific \[[@r46]\].

Mutation screening of a gene is normally performed for 2 reasons: a) to implicate the gene as a cause of a particular disease, and b) to identify as many mutations as possible for the purpose of understanding the genotype- phenotype relationships. It can be used to compare mutation profiles among different populations and for constructing practical genetic tests for clinical use \[[@r34]\]. Further, discovery of the range of mutation types and their locations may shed more light on the little known normal function of myocilin protein \[[@r47]\] and could contribute to the rapidly accruing knowledge on the pathogenic roles of *MYOC* in causation of POAG \[[@r2],[@r47]-[@r49]\]. Identification of a specific mutation or mutations responsible for a patient's disease will solidify diagnosis and may help predict clinical course of the disease \[[@r47]\].

An average mutation frequency of \~1.4 -- 4.6% in *MYOC* among POAG subjects \[[@r4],[@r32],[@r35],[@r38]\] has been reported from around the world. In studies on Indian patients, *MYOC* mutations have been observed at a frequency of \~7.1% \[[@r50]\], and 2% \[[@r51]-[@r53]\]. Most of the mutations (90%) have been observed to be present on exon III of *MYOC* \[[@r46],[@r54]\]. The importance of exon I was highlighted by the observation of the Arg46Stop mutation which is second most common mutation, after Gln368Stop mutation. The Arg46Stop mutation has been reported only among Asians \[[@r46]\]. The importance of the exon I of *MYOC* among Indian POAG patients is evident due to the Gln48His variant. As of date the Gln48His has been reported only among POAG patients from India \[[@r50],[@r52],[@r55]\] and not from any other part of the world.

The Gln48His mutation has been reported among patients from Chennai (South India), Bangalore (South India), and Kolkata (Eastern India) \[[@r46],[@r51],[@r56]\]. However, this mutation was absent in patients from farther South of Chennai \[[@r49]\]. We also did not observe the Gln48His mutation in our mutation analysis of patients from Kanyakumari district (KK dist), South of Chennai \[[@r53]\]. We extended our mutation analysis to include POAG patients from Chennai to compare the mutation types and frequencies among the two places of South India.

Methods
=======

Clinical samples
----------------

The institutional human ethical committee of Dr. ALMPGIBMS, University of Madras, Taramani Campus, Chennai, India, approved the study pattern. Informed consent was obtained from each individual before blood was drawn. One hundred patients from Kanyakumari district \[[@r53]\], and 101 patients from Chennai, diagnosed to have adult/juvenile-onset primary open angle glaucoma (JOAG) were recruited for the study. Among the 101 patients from Chennai, one of them (sample code; BSR-16) was a JOAG patient, native of Kolkata (eastern India), but was residing in Chennai. Among the 100 patients (native of Chennai), eighty seven were adult onset POAG and 13 were JOAG patients. Twenty two of the patients had at least one family member affected by POAG. In two cases the family history of the disease could not be confirmed. The patient, BSR-16, was included in the present study because of the early age of onset and severity of the disease. The patient also had a family history of the disease. Equal number of age, sex, and location matched controls were included in the study. Mean age of patients (n=201) at sample collection was 58.6±13.5 (mean±SD) years (Chennai- 59.8±14 years; KK district- 57.4±13.3 years), while that of controls (n=201; Chennai=101; KK district=100) was 58.9±14.4 years (Chennai- 60±14.8 years; KK district- 57.8±14.2 years). Among the individuals, 62.7% were males (Chennai- 70.3%; KK district- 55%) both among patients and controls. Proportion of male to female POAG patients were different when compared between Chennai (71 males, 30 females) and KK dist (55 males, 45 females); p=0.029 (Fisher's exact test using GraphPad Prism version 5 for Windows; GraphPad Software, San Diego, CA). There were no other significant differences.

A complete ophthalmic examination which consisted of measurement of IOP, gonioscopic evaluation of the angle, examination and documentation of the optic disc, and the visual field (VF) testing was performed by certified ophthalmologists. Visual field testing was done using Humphreys automated field analyzer and/or Bjerrum's tangent screen manual kinetic perimetry. Three or more contiguously missed points on automated perimetry tests (repeatedly) were taken as a VF defect \[[@r57]\]. Visual field examinations using Bjerrum's (Tangent) screen, grading and reporting of the results were conducted by certified and experienced ophthalmologists. Localized arcuate area defects or greater, consistent with glaucomatous cupping and no other identifiable cause for the same were regarded as glaucomatous VF defects. The criteria for diagnosing glaucoma were based on earlier reports \[[@r53],[@r58]\]. Classification of adult and juvenile types of POAG was based on the age of disease onset being ≥40 years or \<40 years of age, respectively \[[@r2],[@r58],[@r59]\].

Analysis of *MYOC*
------------------

Genomic DNA was isolated from the blood samples of patients and controls using the salting out method of Miller et al. \[[@r60]\] Eight primer sets ([Table 1](#t1){ref-type="table"}) were designed to amplify *MYOC* in fragments of \<300 bp \[[@r53]\] for single strand conformation polymorphism (SSCP) analysis. PCR amplifications were performed in 20 µl reaction volumes containing \~100 ng of genomic DNA, 5 pmol of forward and reverse primers, 2 mM of each dNTP, 0.5 U of Taq polymerase with a standard buffer containing 1.5 mM MgCl~2~. Amplification was performed as per the conditions mentioned previously \[[@r53]\]. Briefly, these conditions include initial denaturation at 94 °C for 5 min, followed by 30 cycles of denaturation (94 °C, 30 s), annealing (primer pair dependent temperature - Table 1, 30 s), and extension (72 °C, 30 s) each, followed by a final extension of 2 min at 72 °C.

###### Primer sequences used to amplify the *MYOC* gene in fragments of \<300 base pairs along with primer name, annealing temperature (Ta) for each primer pair and the expected product size.

  **Primer name**   **Sequence**                        **Ta (degree Celsius)**   **Product Size (base pairs)**
  ----------------- ----------------------------------- ------------------------- -------------------------------
  RR3               Forward-5'-TGGATTAAGTGGTGCTTC-3\'   58                        227
  RR4               Reverse-5'-TGGCTGATGAGGTCATAC-3'                               
  RR5               Forward-5'-GGATGTCCGCCAGGTTT-3'     60                        260
  RR6               Reverse-5'-CAATGTCCGTGTAGCCAC-3'                               
  RR7               Forward-5'-TGGCTACCACGGACAGTT-3'    62                        243
  RR8               Reverse-5'-GAGGTGTAGCTGCTGAC-3'                                
  RR9               Forward-5'-CCTTCATCATCTGTGGCA-3'    64                        248
  RR10              Reverse-5'-GTACAGCTTGGAGGCTT-3'                                
  RR1               Forward-5'-AGAGCTTTCCAGAGGAAG-3'    64                        248
  RR2               Reverse-5'-ATGACTGACATGGCCTGG-3'                               
  RR11              Forward-5'-GTCCCAATGAATCCAGCT-3'    62                        268
  RR12              Reverse-5'-TTGCTGTAGGCAGTCTCC-3'                               
  RR13              Forward-5'-GACCAGCTGGAAACCCA-3'     60                        256
  RR14              Reverse-5'-TGCTGAACTCAGAGTCC-3'                                
  RR15              Forward-5'-CATAGTCAATCCTTGGGC-3'    64                        231
  RR16              Reverse-5'-TAAAGACCACGTGGGCAC-3'                               

The amplicon products were mixed with the loading dye (bromophenol blue + xylene cyanol + formamide + Na~2~EDTA) and double distilled water in the following ratio (2 μl + 2 μl + 16 μl; amplicon + dye + dd water), heat denatured for 5 min in boiling water and electrophoresed on a composite (acrylamide, bis acrylamide + agarose) gel \[[@r61]\] for 13 to 14 h. The percentage of the gels used and the electrophoresis voltage varied for amplicons of the different primers sets. Gels were silver stained as per the protocol of Bassam et al. \[[@r62]\] The amplicons with a mobility shift were reamplified, column purified and sequenced using dye termination chemistry and read using the 96 capillary 3730x1 DNA analyzer (Applied Biosystems, Carlsbad, CA). Sequences were analyzed using [BLAST](http://blast.ncbi.nlm.nih.gov/Blast.cgi) to identify the variation(s).

The DNA sequences with a variation were translated in silico to obtain the corresponding amino acid sequences. The amino acid sequences were subjected to the secondary structure prediction using the Garnier Osguthorpe Robson ([GOR](http://molbiol.soton.ac.uk/compute/GOR.html)) prediction method \[[@r63],[@r64]\]. Further, motifs and modifications sites were predicted using [PROSITE](http://prosite.expasy.org/) and [MotifScan](http://myhits.isb-sib.ch/cgi-bin/motif_scan).

Results
=======

A total of five different mutations and two polymorphisms were observed among patients from Kanyakumari district \[[@r53]\], and Chennai ([Table 2](#t2){ref-type="table"}). All the sequence changes have been submitted to [dbSNP](http://www.ncbi.nlm.nih.gov/projects/SNP/) and accession numbers included in [Table 2](#t2){ref-type="table"}. There were no significant differences (p\>0.05) between various cohorts with mutations versus those without mutations using Fisher's exact test (contingency table analysis, [GraphPad Prism](http://www.graphpad.com) version 5). Some of the cohort comparisons are listed below;

###### Comparison of *MYOC* gene mutations and polymorphisms (with dbSNP accession numbers) observed among POAG patients from Chennai and Kanyakumari district of South India.

  ** **          ** **            **Mutations**                                                                                 **Polymorphisms**                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  -------------- ---------------- --------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  **Location**   **Group**        **Gln48His**[ss295476454](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476454)   **Ser331Thr**[ss295476451](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476451)   **Thr353Ile**[ss295476455](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476455)   **Pro370Leu**[ss295476453](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476453)   **Asn480Lys**[ss295476456](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476456)   **Thr325Thr**[ss295476450](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476450)   **Try347tyr**[ss295476452](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=295476452)
  Chennai        Patients n=101   2                                                                                             0                                                                                              1                                                                                              0                                                                                              1                                                                                              0                                                                                              0
                 Controls n=101   0                                                                                             0                                                                                              0                                                                                              0                                                                                              0                                                                                              0                                                                                              0
  KK District    Patients n=100   0                                                                                             1                                                                                              0                                                                                              1                                                                                              0                                                                                              1                                                                                              4
                 Controls n=100   0                                                                                             0                                                                                              0                                                                                              0                                                                                              0                                                                                              0                                                                                              0

1.  Total number of patients with mutations (5 of 201) versus number of controls with mutations (0 of 201); p=0.06;

2.  JOAG patients with mutations (2/27; including subject BSR-16) versus adult onset POAG patients with mutations (3/174), p=0.13;

3.  Male patients with mutations (3/126) versus female patients with mutations (2/75), p=1;

4.  Number of mutant Chennai patients (2/100; excluding subject BSR-16, not native of Chennai) versus number of mutant KK dist patients (2/100); p=1;

5.  Chennai patients with mutations (2/100; excluding BSR-16, not native of Chennai) versus Chennai controls with mutations (0/101), p=0.24;

6.  KK dist patients with mutations (2/100) versus KK dist controls with mutations (0/100), p=0.49.

All mutations observed among patients were in the heterozygous state and were absent in controls. Two different mutations, Pro370Leu and Ser331Thr, were observed in patients from Kanyakumari district, of which Ser331Thr was a novel variant. These two mutations, Pro370Leu and Ser331Thr, have been reported and discussed earlier \[[@r53]\] and hence are not discussed here. Three different mutations were observed among the 101 patients from Chennai.

*MYOC* Gln48His
---------------

Two patients from Chennai (Sample Codes; Eg-17 and Eg-10) had the Gln48His variation ([Figure 1](#f1){ref-type="fig"}). The Gln48His variation is a 144 G\>T transversion which resulted in a non-conservative amino acid substitution, glutamine (Gln) to histidine (His). Presence of this mutation in patients and absence in controls indicates that this variant might play a disease causative role.

![Heterozygous Gln48His mutation in *MYOC*. Chromatogram sequence derived from patient Eg-10 with the G\>T transversion (indicated by arrow) compared to the normal control.](mv-v17-3243-f1){#f1}

Age of onset of glaucoma was at 63 years for patient Eg-17. He had raised intraocular pressures and glaucomatous optic neuropathy ([Table 3](#t3){ref-type="table"}). Visual field tests revealed constricted fields in the right eye and tubular vision in the left eye. The patient was under medication - Iobet 0.5%. The patient Eg-10 had been diagnosed for POAG a year earlier (age of onset, 43). The patient had a raised IOP and increased cup/disc ratio in the right eye. The patient had an enlarged Blind Spot (BS) in the left eye and ≤35° vision in the right eye. The pressures were reduced to normal levels, 17.4 (OD)/7.2 (OS) mmHg after medication (Iobet 0.5%).

###### Clinical details of South Indian POAG patients with *MYOC* mutations.

  **Patient**   **Mutation**   **Age (at diagnosis)**   **GON- C/D ratio**   **BCVA**   **GVFD**   **IOP (mm Hg) at diagnosis**   **Medication/ Surgery**   **Family history**                                
  ------------- -------------- ------------------------ -------------------- ---------- ---------- ------------------------------ ------------------------- -------------------- -------- ------ ------------ -----
  Eg-17         Gln48His       63                       0.7                  0.8        6/6        LPP                            \+                        \+                   22       26     Medication   No
  Eg-10         Gln48His       43                       0.9                  0.4        6/9        6/6                            \+                        EBS                  24.4     14.6   Medication   No
  BSR-16\*      Thr353Ile      14                       0.9                  1          6/9        NLP                            \+                        Blind                21\*\*   \-     Surgery      Yes
  BSR-16\*      Asn480Lys      14                       0.9                  1          6/9        NLP                            \+                        Blind                21\*\*   \-     Surgery      Yes
  Ngl-12\#      Ser331Thr      68                       0.9                  1          6/6        LPP                            \+                        \+                   20.6     20.6   Medication   No
  R-6\#         ProLeu370      16                       \-                   \-         NLP        NLP                            Blind                     Blind                \-       \-     \-           Yes

\* - Undergone surgery when blood samples were collected at the age of 34. \*\* - IOP at sample collection (IOP data at diagnosis, not available). ^\#^ - Published data \[[@r46]\]. Abbreviations: GVFD- Glaucomatous visual field defect; GON- Glaucomatous optic neuropathy; BCVA- Best corrected visual acuity, using Snellen chart, at time of sample collection; LPP- Light perception with projection; NLP- No light perception (blind); EBS- Enlarged blind spot.

The other patient with mutations (BSR-16, from Kolkata) turned out to be a compound heterozygote. Two mutations, Thr353Ile and Asn480Lys, both in the heterozygous state were observed in exon III of *MYOC*.

*MYOC* Thr353Ile
----------------

This mutation is a heterozygous C\>T transition in nucleotide 1058 ([Figure 2A](#f2){ref-type="fig"}) which resulted in a threonine to isoleucine change. This results in change in polarity. This has been reported earlier among POAG patients and control subjects from Asia \[[@r4]\]. However in our study this was not observed in controls.

![Chromatograms depicting *MYOC* gene sequence changes in a compound heterozygote POAG patient from India. **A**: Heterozygous The353Ile mutation in *MYOC*. Chromatogram sequence derived from patient BSR-16 with the C\>T transition (indicated by arrow) compared to the normal control. **B**: Heterozygous Asn480Lys mutation in *MYOC*. Chromatogram sequence derived from patient BSR-16 with the C\>A transversion (indicated by arrow) compared to the normal control.](mv-v17-3243-f2){#f2}

*MYOC* Asn480Lys
----------------

This mutation, asparagine (polar amino acid) to lysine (positively charged amino acid), is a result of a heterozygous C\>A transversion at nucleotide 1440 ([Figure 2B](#f2){ref-type="fig"}). This variant has been reported from other populations \[[@r31]\]. Founder effect for this mutation has also been reported \[[@r31]\].

The patient BSR-16 had an early age of onset of the disease (diagnosed at age 14). She had rapid progression of the disease and before POAG could be diagnosed and treated (trabeculectomy) she had lost the vision of her left eye and had a considerable vision loss in the right eye. She had been diagnosed and treated elsewhere initially, before finally visiting one of the hospitals involved in the present study. The pressure in her right eye during the blood collection was 21 mmHg. The optic cup/disc ratio was 0.9 in the right eye with a totally excavated disc in the left eye ([Table 3](#t3){ref-type="table"}). The patient was blind in the left eye and had \~25° vision in the right eye ([Figure 3](#f3){ref-type="fig"}). A positive family history of POAG was recorded based on the patient's information.

![Humphreys visual field chart showing the visual field damage in the right eye of patient BSR-16, a compound heterozygote with two mutations in exon III of *MYOC*.](mv-v17-3243-f3){#f3}

Secondary structure prediction using GOR showed changes in the predicted structure among all the mutant protein sequences. Further, other tools to predict the modification sites namely PROSITE and MotifScan identified the presence of motifs/ modifications sites possibly being affected as a result of these secondary structural changes. The effects of the mutations based on the prediction using softwares have been shown in [Table 4](#t4){ref-type="table"}.

###### Predicted effects of the observed *MYOC* mutations on secondary structure, putative motifs, and modification sites of the myocilin protein.

  **Mutation**   **Predicted effect of mutation on secondary structure and on motifs/modification sites**
  -------------- ------------------------------------------------------------------------------------------
  Gln48His       Loss of sheet, gain of turn near to the PKC site (44--46 amino acids)
  Ser331thr      Change in predicted secondary structures of the mutant protein
  Thr353Ile      Loss of PKC site at 353--355
  Pro370Leu      Loss of turn near to CK site (377--380)
  Asn480Lys      Change in charge, gain of α-helix at CK2 site (475--478)

Sequencing of 10 random samples using each primer set confirmed the results of SSCP analysis.

Discussion
==========

The mutation frequency in *MYOC* among POAG patients in this study was 2.48%. The mutation frequency observed among patients from Chennai was 2% (2 of 100; excluding the patient BSR-16 who originated from Kolkata, eastern part of India). A similar mutation frequency of 2% among POAG patients from kanyakumari district was reported earlier \[[@r53]\]. These observed mutation frequencies are similar to those reported from other populations in India \[[@r39],[@r50],[@r52],[@r53]\] and rest of the world \[[@r4],[@r38]\].

The presence of the *MYOC* Gln48His mutation among POAG patients from Chennai at a frequency of 2% conforms to earlier reports \[[@r39],[@r52]\] and reiterates the importance and possible disease causing role of *MYOC*, especially exon I, among Indian POAG patients. The *MYOC* mutation frequency was much higher, 5.35% (3/56), in a study on POAG patients from Kolkata (eastern part of India) \[[@r50]\]. The frequency was lower at 0.8% in a study on patients from a different part of South India \[[@r56]\]. The Gln48His mutation has not been reported from any other population in the world so far.

Among patients from the KK district (the southern-most part of India) the Gln48His mutation was not observed \[[@r53]\]. In an earlier study by Kanagavalli et al. \[[@r51]\] the Gln48His mutation was not observed among patients from Madurai (farther south of Chennai and closer to the KK district). This suggests the possible involvement of demographic factors in causation of POAG (via the Gln48His mutation). Further, there are no reports of this variant being present in families. Inconsistency in the presence/absence of Gln48His and its prevalence among different populations in India makes it difficult to comprehend its role in disease causation.

It is essential to screen more patients from South India to confirm or rule out association of the Gln48His mutation with demographic factors. A proper mutation frequency is a prerequisite to initiate the screening of such region-specific mutations as a clinical diagnostic tool. Thus screening of Gln48His among POAG patients from other parts of India is also essential to establish it as a potential diagnostic tool for this part of the world. Since the Gln48His mutations have not been reported in familial cases from India, families with POAG must also be screened thoroughly to rule out or confirm the involvement of this mutation in familial cases.

Predictions using bioinformatics' tools revealed changes in the secondary structure of the Gln48His mutant protein close to a putative phosphorylation (PKC) site at amino acids 44--46. Further, the cysteine at the 47th amino acid has been proposed to be involved in oligomerization of myocilin \[[@r65]\]. The predicted secondary structural changes due to the Gln48His mutation could hinder oligomerization via the cysteine residue (47th amino acid) thereby resulting in aberrant functioning of the protein. Functional studies are required to deduce the actual effect of the Gln48His mutation.

In this study two sequence variants in the same exon (exon III) of *MYOC* were observed in a POAG patient. The patient was a native of Kolkata (eastern part of India). The mutation frequency of *MYOC* is high among POAG patients of the eastern part of India \[[@r50]\]. Our study is the first report of a compound heterozygote with two mutations in the same exon (exon III) of *MYOC*. The occurrence of two variants (both resulting in amino acid changes) in different exons of the *MYOC* gene has been reported earlier \[[@r36]\] wherein the individual had a severe phenotype including an aggressive form of POAG and an early age of onset (14 years of age). The individual had a disease causing variation namely Lys423Glu (familial), and the Arg126Trp in exon I which had been observed in controls as well \[[@r36]\]. Two compound heterozygote POAG patients for the *CYP1B1* gene have been reported in one study \[[@r56]\].

Similar to the Arg126Trp in the earlier reported compound heterozygote \[[@r36]\], the Thr353Ile has been reported in controls \[[@r4]\] though not in our study and has been associated with an intermediate disease phenotype \[[@r4],[@r66]\]. The other mutation Asn480Lys in our compound heterozygote has been reported in other studies as well and has also been associated with an intermediate disease phenotype \[[@r67],[@r68]\]. Further, the Asn480Lys mutation has earlier been reported to be associated with families and to have a founder effect, (reviewed by Gong et al. \[[@r46]\]).

The compound heterozygote individual, BSR-16, had a positive family history and a severe disease phenotype. The patient, BSR-16, had an early age of disease onset (14 years of age) and aggressive form of the disease with rapid progression which was comparable to that reported earlier \[[@r36]\]. Efforts to screen the family for mutations proved futile as the members were not approachable (in terms of location and other factors) for blood samples. Presence of two variants in the same individual and the presence of a severe phenotype suggest a combinatorial role of the two variations in disease causation. This observation in the Kolkata patient, along with the earlier report of a high mutation frequency in *MYOC* of POAG patients from Kolkata \[[@r50]\], indicate the stronger association of *MYOC* with POAG in the eastern part of India compared with the other parts.

An early age of disease onset and rapid progression of the disease has also been observed in some patients with an apparently normal *MYOC* gene. These observations indicate the possible role of other genes in causation of POAG. However, in the case of patient BSR-16, the combinatorial effect of the 2 mutations cannot be ruled out. Both variants had either a predicted alteration of protein secondary structure that overlapped a putative phosphorylation (CK2) site or predicted alteration of a phosphorylation (PKC) site ([Table 4](#t4){ref-type="table"}). Functional analyses of the mutant proteins are essential to confirm the importance of these predicted alterations in putative modification sites or changes in secondary structure altering overlapping/ nearby motifs or modification sites.

Mutations in presently known genes account for only a low percentage of all POAG cases (less than 10%) \[[@r29]\]. About 5% of POAG is caused by mutations in myocilin or optineurin \[[@r47]\]. Hence, more extensive genetic studies are required to identify other genes involved and to understand the molecular mechanisms of the disease. Most cases of primary open angle glaucoma are complex and multi-factorial \[[@r47]\], hence the role of epigenetic processes such as DNA methylation and histone modifications along with small interfering RNA cannot be ruled out and have to be addressed to better understand the complete mechanism of disease onset and prognosis.
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